BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33938028)

  • 21. Exophthalmos in a young woman with no graves' disease - a case report of IgG4-related orbitopathy.
    Erdei A; Steiber Z; Molnar C; Berenyi E; Nagy EV
    BMC Ophthalmol; 2018 Jan; 18(1):5. PubMed ID: 29329570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. VARIABLES AFFECTING THE LONG-TERM OUTCOME OF GRAVES ORBITOPATHY FOLLOWING HIGH-DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY.
    Leo M; Mautone T; Ionni I; Profilo MA; Sabini E; Menconi F; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
    Endocr Pract; 2016 Oct; 22(10):1177-1186. PubMed ID: 27732097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sight-Threatening Graves' Ophthalmopathy during the Third Trimester of Pregnancy: A Case Report.
    Sakurai K; Inoue T; Niitsuma S; Sato R; Takahashi K; Arihara Z
    Tohoku J Exp Med; 2020 Dec; 252(4):321-327. PubMed ID: 33268601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves' ophthalmopathy.
    Zhu W; Ye L; Shen L; Jiao Q; Huang F; Han R; Zhang X; Wang S; Wang W; Ning G
    J Clin Endocrinol Metab; 2014 Jun; 99(6):1999-2007. PubMed ID: 24606088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Features of Graves' Ophthalmopathy and Impact of Enalapril on the Course of Mild Graves' Ophthalmopathy: A Pilot Study.
    Ataabadi G; Dabbaghmanesh MH; Owji N; Bakhshayeshkaram M; Montazeri-Najafabady N
    Endocr Metab Immune Disord Drug Targets; 2020; 20(1):139-148. PubMed ID: 31345156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement of the MRI and clinical features of Asian Graves' ophthalmopathy by radiation therapy with steroids.
    Ma Z; Ozaki H; Ishikawa Y; Jingu K
    Jpn J Radiol; 2019 Aug; 37(8):612-618. PubMed ID: 31201593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Short-term efficacies of intravenous glucocorticoid therapy for moderate-to-severe Graves' ophthalmopathy].
    Guo L; Yang G; Gu W; Jin N; Chen K; Du J; Wang X; Ouyang J; Dou J; Ba J; Lü Z; Mu Y
    Zhonghua Yi Xue Za Zhi; 2015 May; 95(20):1572-5. PubMed ID: 26463604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.
    Sisti E; Menconi F; Leo M; Profilo MA; Mautone T; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
    J Endocrinol Invest; 2015 Jun; 38(6):661-8. PubMed ID: 25596664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination Therapy of Intravenous Steroids and Orbital Irradiation is More Effective Than Intravenous Steroids Alone in Patients with Graves' Orbitopathy.
    Oeverhaus M; Witteler T; Lax H; Esser J; Führer D; Eckstein A
    Horm Metab Res; 2017 Oct; 49(10):739-747. PubMed ID: 28922676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence That Baseline Levels of Low-Density Lipoproteins Cholesterol Affect the Clinical Response of Graves' Ophthalmopathy to Parenteral Corticosteroids.
    Naselli A; Moretti D; Regalbuto C; Arpi ML; Lo Giudice F; Frasca F; Belfiore A; Le Moli R
    Front Endocrinol (Lausanne); 2020; 11():609895. PubMed ID: 33414766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low signal intensities of MRI T1 mapping predict refractory diplopia in Graves' ophthalmopathy.
    Matsuzawa K; Izawa S; Kato A; Fukaya K; Matsumoto K; Okura T; Miyazaki D; Kurosaki M; Fujii S; Taniguchi SI; Kato M; Yamamoto K
    Clin Endocrinol (Oxf); 2020 Jun; 92(6):536-544. PubMed ID: 32090348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased serum VEGF and b-FGF in Graves' ophthalmopathy.
    Ye X; Liu J; Wang Y; Bin L; Wang J
    Graefes Arch Clin Exp Ophthalmol; 2014 Oct; 252(10):1639-44. PubMed ID: 24867311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy.
    Aktaran S; Akarsu E; Erbağci I; Araz M; Okumuş S; Kartal M
    Int J Clin Pract; 2007 Jan; 61(1):45-51. PubMed ID: 16889639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
    Wiersinga WM
    Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
    Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
    Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of orbital radiotherapy in moderate-to-severe active graves' orbitopathy including long-lasting disease: a retrospective analysis.
    Choi JH; Lee JK
    Radiat Oncol; 2020 Sep; 15(1):220. PubMed ID: 32958019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Orbital magnetic resonance imaging combined with clinical activity score can improve the sensitivity of detection of disease activity and prediction of response to immunosuppressive therapy for Graves' ophthalmopathy.
    Tachibana S; Murakami T; Noguchi H; Noguchi Y; Nakashima A; Ohyabu Y; Noguchi S
    Endocr J; 2010; 57(10):853-61. PubMed ID: 20733265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extraocular muscle repositioning as the last therapeutic option for a patient with a severe course of Graves' Ophthalmopathy: a case report.
    Rau A; Klopfer M; Rommel N; Rau-Fornefeld M; Kolk A
    BMC Ophthalmol; 2018 Feb; 18(1):56. PubMed ID: 29482520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum levels of soluble Fas in patients with Graves' ophthalmopathy.
    Ohtsuka K; Hashimoto M
    Br J Ophthalmol; 2000 Jan; 84(1):103-6. PubMed ID: 10611108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.